Foundational · Pharmacogenomics

Atlas PGx.

Your medication, deciphered.

Pharmacogenomic profile based on the UKB Bonn / AXELERIS pipeline. 26 genes, evidence-based recommendations across 75+ active substances. Designed for review with your physician.

WHICH PART OF YOUR BODY

Which part of your body.

Drug categories
  • Pain medication
  • Blood thinners
  • Cardiovascular drugs
  • Antidepressants
  • Chemotherapy
  • Immunosuppressants
WHAT THIS PANEL ANSWERS

What this panel answers.

How does your body metabolize the drugs your doctor might prescribe you, now or in the future?

WHAT CHANGES IF A FINDING IS IDENTIFIED

What changes if something is found.

  1. Warfarin dosing (VKORC1, CYP2C9): the correct starting dose prevents bleeding and clotting complications.
  2. Clopidogrel response (CYP2C19): identifies poor metabolizers for whom alternative antiplatelet agents work better after a heart event or stent.
  3. Codeine and tramadol (CYP2D6): identifies ultra-rapid metabolizers at risk of overdose and poor metabolizers for whom the drug does not work.
  4. Capecitabine and 5-FU chemotherapy (DPYD): identifies patients who require dose reduction to prevent severe toxicity.
  5. Antidepressant selection (CYP2D6, CYP2C19): informs SSRI and tricyclic-antidepressant choice and dose.
Pathway references
  • CPIC
  • DPWG
GENES ANALYZED

What is analyzed.

Atlas analyzes each gene in its entirety -- not just hotspot regions -- against current clinical literature. Findings are reviewed by a board-certified medical geneticist before release.

PRV08

Pharmacogenetics

21 genes

A CPIC- and DPWG-aligned pharmacogenetics panel covering the genes that most often change how a body activates, clears, or reacts to common medications. Used by physicians to choose drug and dose before prescribing, particularly for cardiology, oncology, psychiatry, and pain management.

Clinical areas covered
  • Warfarin dosing (VKORC1, CYP2C9)
  • Clopidogrel response (CYP2C19)
  • Codeine and tramadol metabolism (CYP2D6)
  • 5-FU and capecitabine toxicity (DPYD)
  • Thiopurine dosing (TPMT, NUDT15)
  • HLA-mediated drug hypersensitivity (HLA-B*57:01 abacavir, HLA-B*15:02 carbamazepine)
  • Statin myopathy risk (SLCO1B1)
  • Irinotecan toxicity (UGT1A1)
Analyzed genes -- 21 genes
  • ABCG2
  • CACNA1S
  • CYP2B6
  • CYP2C19
  • CYP2C9
  • CYP2D6
  • CYP3A4
  • CYP3A5
  • CYP4F2
  • DPYD
  • G6PD
  • HLA-A
  • HLA-B
  • IFNL4
  • MT-RNR1
  • NUDT15
  • RYR1
  • SLCO1B1
  • TPMT
  • UGT1A1
  • VKORC1
Limitations
  • Pharmacogenetics typically falls outside ISO 15189 accreditation scope -- results are clinical-grade in interpretation but are not an accredited diagnostic in the same sense as the predictive panels.

Gene list per CeGaT PRV08 (2026-05). TODO -- medical/product review required: confirm whether the Atlas PGx product analyzes 21 or 26 genes. Live PGx page currently advertises 26 pharmacogenes; do not overwrite the Atlas 26-gene claim with the CeGaT 21-gene list without confirmation.

WHY THIS MATTERS

Why early knowledge matters.

  • PRV08

    Pharmacogenetics

    Roughly 99% of people carry at least one actionable pharmacogenetic variant. Knowing yours can prevent a non-response, an avoidable side effect, or a serious hypersensitivity reaction -- and it carries forward across every prescription you may receive over a lifetime.

RESULT INTERPRETATION

How findings are reported.

Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.

  1. 01

    Pathogenic variant

    Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.

  2. 02

    Likely pathogenic variant

    Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.

  3. 03

    Variant of uncertain significance (VUS)

    Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.

  4. 04

    No relevant variant in this panel

    No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.

  5. 05

    Family implications

    When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.

Counseling and cascade testing

Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). Atlas Counseling provides this before and after the test. When an actionable finding has implications for relatives, your counselor will discuss cascade testing -- not Atlas alone.

CLINICAL LIMITATIONS

What this test does not do.

  • Not a diagnosis of active disease

    A variant indicates predisposition. It does not confirm a condition is currently present.

  • Does not replace screening or routine care

    Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.

  • Not all risk is genetic

    Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.

  • A negative result does not eliminate risk

    Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.

  • Clinical decisions remain with your physician

    Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.

GenDG §7

Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. Atlas Counseling is included in the order flow.

What the report contains

Every drug, matched to your metabolism.

Three examples from a typical Atlas Pharmacogenomics report. Each medication is graded against CPIC and DPWG guidelines and tied to a specific clinical implication.

Example · Antiplatelet therapy

Clopidogrel — CYP2C19 *2/*17

Cardiovascular · CPIC Level 1A

Gene
CYP2C19
Diplotype
*2/*17 — Intermediate metabolizer
PharmGKB annotation
Level 1A
CPIC guideline
Avoid clopidogrel; use alternative antiplatelet (prasugrel, ticagrelor) for ACS / PCI
Clinical impact
Reduced platelet inhibition, elevated cardiovascular event risk
Population frequency
≈30% intermediate metabolizers (European descent)

CYP2C19 governs the conversion of clopidogrel to its active thiol metabolite. Atlas Pharmacogenomics flags intermediate and poor metabolizers as severe and surfaces the alternative therapies in the clinical recommendations section.

Example · Pain management

Codeine — CYP2D6 (variant detected, activity score 0.25–1)

Analgesia · CPIC Level 1A

Gene
CYP2D6
Phenotype
Reduced metabolizer
Clinical impact
Reduced morphine conversion, diminished analgesia at standard doses
CPIC guideline
Use alternative non-codeine opioid for pain management; tramadol also affected
Patient context
Surgical pain, post-operative analgesia, chronic pain protocols

CYP2D6 is the primary route of conversion from codeine to morphine. Atlas Pharmacogenomics reports the predicted phenotype, the underlying star alleles, and the guideline-level recommendation in plain clinical language so the prescribing decision stays with the physician.

Example · Endocrine cancer therapy

Tamoxifen — CYP2D6

Oncology · CPIC Level 1A

Gene
CYP2D6
Phenotype
Reduced metabolizer
Clinical impact
Lower endoxifen formation, increased recurrence risk and reduced event-free survival in adjuvant therapy
CPIC guideline
Consider alternative hormone therapy (aromatase inhibitor) for postmenopausal patients
Note
Genotype-guided therapy increasingly recommended in estrogen-receptor-positive breast cancer

Endoxifen is the principal active metabolite of tamoxifen and depends on CYP2D6 activity. Atlas Pharmacogenomics pairs the genotype with concrete co-medication warnings (strong CYP2D6 inhibitors should be avoided) so this nuance reaches the prescriber.

Positioning

What this is — and what it isn't.

What Pharmacogenomics is
  • Pharmacogenomic profiling against established clinical guidelines (CPIC, DPWG)
  • Structured medication response report for physician review
  • Reference material for prescribing decisions
  • Cited, transparent, reproducible
What Pharmacogenomics is not
  • Medical advice, diagnosis, or treatment recommendation
  • A substitute for clinical pharmacology consultation
  • A directive to change medications without physician supervision
  • Predictive of all medication responses

We genotype. Your physician prescribes.

Methodology

Built with University Hospital Bonn.

Atlas Pharmacogenomics is delivered on a validated pharmacogenomics annotation pipeline developed at a leading German university genetics center, using the AXELERIS workflow. Sample, platform, analysis, and standards are documented end-to-end.

  • Sample — Buccal swab (cheek swab), at-home collection
  • Platform — Illumina Microarrays GSA with enhanced PGX v4.0
  • Analysis — validated pharmacogenomics annotation pipeline from a leading German university genetics center (AXELERIS interpretation workflow)
  • Standards — CPIC, DPWG, PharmVar, EMA / FDA / Swissmedic guideline integration
What the report contains

Atlas Pharmacogenomics — Pharmacogenomic Profile.

A clinically reviewed PDF organised so a prescriber can find what they need in seconds. Severe effects surface first; the underlying genotype and guideline citations are always one page away.

Atlas PGx — Pharmacogenomic ReportPDF · preview
  1. §01Executive summary (drugs by impact tier)
  2. §02Severe pharmacogenomic effects (contraindications)
  3. §03Moderate effects (dosing adjustments)
  4. §04Mild effects (monitoring recommendations)
  5. §05Phenotype profile (26 genes, diplotypes, activity scores)
  6. §06Genotyping results (HGVS nomenclature)
  7. §07Scientific basis & references
Pricing

Coming soon.

Pricing finalized at launch
Report will be priced at launch — pricing TBD

Atlas Pharmacogenomics launches in the next phase of Atlas Protocol. Join the waitlist and we'll email you the moment it's live, with founding-customer pricing available to the first cohort.

Pricing finalized at launch. Founding-customer pricing reserved for the waitlist.
FAQ

Questions

Looking for clinical risk panels?

Explore Clinical Prevention